Medical technology manufacturer FEMSelect has leveraged AcuityMD’s platform to expedite the identification and engagement of US-based physicians involved in the treatment of pelvic floor disorders (PFDs).

At least one in five women suffer from PFDs. According to a study conducted last year involving more than 25,000 women, approximately 32% had a PFD.

The partnership with AcuityMD, a novel commercial platform for medical technology companies, will enable FEMSelect to break into the US market.

FEMSelect is an Israel-based startup that specialises in a minimally invasive approach for the treatment of patients with PFDs.

Unlike the existing standard of care for pelvic organ prolapse, which comprises a full hysterectomy or complex mesh surgery, FEMSelect’s EnPlace provides a minimally invasive, meshless approach to physicians.

The company selected AcuityMD’s commercial platform to achieve faster and more accurate physician identification and planning for the efficient commercialisation of its technology.

FEMSelect co-CEO Debbie Garner said: “Our lean sales team has a lot of territories to cover in a short period of time, so we needed advanced technology to help us identify the microcosm of about 2,500 relevant specialists in the US.

“AcuityMD’s unique domain expertise, an aggregated database of various sources including private and public payers and a user-friendly interface, made it an easy choice. Our sales team depends on the platform not just for physician identification but also for smart engagement strategies.”

The AcuityMD platform helped FEMSelect to identify more than 400 healthcare providers and 600 sites of care within one month.

FEMSelect market development manager Francesca Babore said: “AcuityMD’s platform is continuously updated to add new data and rich functionality.

“It also saves our sales team a tremendous amount of time and gets very granular with its insights about specialists based on surgical experience and relevant patient populations for strategic call planning.”